Brookings Institution Analysis Examines Profitability Of New Drug Development For Neglected…

Brookings Institution’s “TechTank”: Are drugs for neglected diseases profitable? Jake Schneider, research assistant, and Jeremy Barofsky, non-resident fellow in governance studies, both with Brookings, discuss their new analysis in which they examine the profitability of new drugs for neglected diseases “using various incentive mechanisms.” They write, “Ultimately, we recommend necessary policy proposals to improve what…More

Go here to read the rest:
Brookings Institution Analysis Examines Profitability Of New Drug Development For Neglected…